TheraRadar
← Back
Data updated: Sep 20, 2026

HONG KONG

Pharma
RespiratoryInfectious DiseaseOncology Execution: Fair

HONG KONG is a pharmaceutical company focused on Respiratory, Infectious Disease, Oncology. Key products include XENLETA.

2004
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2019)
1 Novel 1 Priority Review 1 Fast Track
See 1 novel approval →
2019 XENLETA (LEFAMULIN ACETATE) Priority Review · Fast Track

HONG KONG at a Glance

  • Growing R&D activity with 28 trials in last 2 years

HONG KONG's Key Drugs

HONG KONG's core commercial portfolio centers on XENLETA, spanning Respiratory and Infectious Disease — its most strategically important drugs approved in the last 15 years.

XENLETA
Infectious Disease
Approved 2019

HONG KONG's Recent FDA Approvals

New NDA/BLA approvals for HONG KONG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HONG KONG's Therapeutic Areas

HONG KONG's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 28%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1
Infectious Disease 25%
0 drugs Phase 3: 1 Phase 2: 2
Oncology 19%
0 drugs Phase 1: 6
Metabolic 16%
0 drugs Phase 2: 2 Phase 1: 1
Immunology 13%
0 drugs Phase 2: 2

HONG KONG Pipeline Snapshot

HONG KONG has 18 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 8 Phase 2 and 8 Phase 1.

2
Phase 3
8
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • XENLETA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 19/31 completed
  • • Speed: 40 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges